Company intelligence / Profile preview

BeneVir Biopharm

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

BeneVir’s lead programs were in preclinical development, utilizing genetically engineered oncolytic herpes simplex viruses to target and destroy cancer cells, aiming to provoke robust anti-tumor immune responses; clinical results beyond proof-of-concept were not publicly reported before acquisition[1][2].

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologic
Industry: Biotech

Partnerships

Johnson & Johnson Innovation LLC (transaction/facilitation)

Beyond the preview

Go deeper on BeneVir Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeneVir Biopharm.

Explore the full profile